Market Cap 26.81B
Revenue (ttm) 0.00
Net Income (ttm) -1.13B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 3,501,600
Avg Vol 2,897,836
Day's Range N/A - N/A
Shares Out 198.17M
Stochastic %K 14%
Beta 1.01
Analysts Strong Sell
Price Target $172.95

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6801
Address:
700 Saginaw Drive, Redwood City, United States
raticals
raticals Apr. 27 at 1:30 PM
$CMPX genuinely asking why is this stock worth a supposed bag of crap but extends life from liver death by 8 months but $RVMD extendes life for pancreatic death by eight month but the stock is worth a mountain of gold?
0 · Reply
Florestan
Florestan Apr. 27 at 6:31 AM
$RVMD $263 for starter. RVMD will go on to become another Merck.
1 · Reply
Skoufc1
Skoufc1 Apr. 27 at 1:08 AM
$RVMD Mentioned on 60 minutes tonight.
0 · Reply
jdlman
jdlman Apr. 26 at 11:43 PM
$RVMD not to late to enter ?
2 · Reply
Skoufc1
Skoufc1 Apr. 26 at 8:36 PM
$RVMD Life Sciences Capital raises price target to.$263 for RVMD.
0 · Reply
Skoufc1
Skoufc1 Apr. 26 at 5:07 PM
$RVMD Life Science has RVMD as a buy and raises PT to $263. I think think this is the highest PT after Stifel bumped it up $215.
0 · Reply
PhantomZ
PhantomZ Apr. 26 at 2:05 AM
$RVMD nice data! Another highly promising Paradigm Shift will be X-ray activation of Rutherin in the destruction of Tumors. 100% CR and survival in animal models. Can’t wait till they release Pancreatic cancer data….https://stockhouse.com/news/press-releases/2026/04/13/theralase-r-reports-complete-response-with-x-ray-activated-rutherrin-r-in-musclec.
1 · Reply
LiveCommander
LiveCommander Apr. 25 at 9:56 PM
People who comment on $RVMD RM-055 preclinical data as predicting replacement to Pan RAS molecule glues should try to understand how the drug works from detailed slides at RVMD website. Daraxonrasib causes some level of GTP hydrolysis and contributes to enhancing RAS off$ERAS and $ANL ) also kill cell lines with RAS amplification. Phase 1 to start in q 4. And people need to stop being ahead of themselves. Although Cool discovery but no details on how it enhances hydrolysis.
0 · Reply
AppleStar
AppleStar Apr. 25 at 8:52 PM
$RVMD It got to $150. I was just two weeks early in this prediction. Looking forward to ASCO in a couple of weeks. Or will they get bought out before?
2 · Reply
BixbyKnolls
BixbyKnolls Apr. 25 at 6:48 PM
$IBRX He thinks $RVMD complimentary to IBRX.
0 · Reply
Latest News on RVMD
Top 2 Health Care Stocks That May Fall Off A Cliff In Q2

Apr 17, 2026, 7:37 AM EDT - 10 days ago

Top 2 Health Care Stocks That May Fall Off A Cliff In Q2

AVNS


This Pill May Help Pancreatic Cancer Patients Live Longer

Apr 15, 2026, 12:10 PM EDT - 11 days ago

This Pill May Help Pancreatic Cancer Patients Live Longer


Revolution Medicines Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 2 months ago

Revolution Medicines Earnings Call Transcript: Q4 2025


Overlooked Stock: RVMD Sells After MRK Turns Away

Jan 26, 2026, 4:30 PM EST - 3 months ago

Overlooked Stock: RVMD Sells After MRK Turns Away

MRK


Merck No Longer in Talks to Buy Revolution Medicines

Jan 25, 2026, 2:30 PM EST - 3 months ago

Merck No Longer in Talks to Buy Revolution Medicines

MRK


AbbVie Near Deal for Revolution Medicines

Jan 7, 2026, 2:48 PM EST - 3 months ago

AbbVie Near Deal for Revolution Medicines

ABBV


Revolution Medicines Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 6 months ago

Revolution Medicines Earnings Call Transcript: Q3 2025


Revolution Medicines Transcript: Study Result

Sep 10, 2025, 5:00 PM EDT - 8 months ago

Revolution Medicines Transcript: Study Result


Revolution Medicines Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 9 months ago

Revolution Medicines Earnings Call Transcript: Q2 2025


Revolution Medicines Transcript: Investor Update

Jun 24, 2025, 8:00 AM EDT - 10 months ago

Revolution Medicines Transcript: Investor Update


Revolution Medicines Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Revolution Medicines Earnings Call Transcript: Q1 2025


Revolution Medicines Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Revolution Medicines Earnings Call Transcript: Q4 2024


Revolution Medicines Transcript: Status Update

Dec 2, 2024, 8:00 AM EST - 1 year ago

Revolution Medicines Transcript: Status Update


Revolution Medicines Earnings Call Transcript: Q3 2024

Nov 6, 2024, 4:30 PM EST - 1 year ago

Revolution Medicines Earnings Call Transcript: Q3 2024


Revolution Medicines Transcript: Study Update

Oct 25, 2024, 12:00 PM EDT - 1 year ago

Revolution Medicines Transcript: Study Update


Revolution Medicines Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Revolution Medicines Earnings Call Transcript: Q2 2024


Revolution Medicines Transcript: Status Update

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Revolution Medicines Transcript: Status Update


Revolution Medicines Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Revolution Medicines Earnings Call Transcript: Q1 2024


Revolution Medicines Earnings Call Transcript: Q4 2023

Feb 26, 2024, 4:30 PM EST - 2 years ago

Revolution Medicines Earnings Call Transcript: Q4 2023


Revolution Medicines Earnings Call Transcript: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

Revolution Medicines Earnings Call Transcript: Q3 2023


Revolution Medicines Transcript: Status Update

Oct 22, 2023, 12:30 PM EDT - 2 years ago

Revolution Medicines Transcript: Status Update


Revolution Medicines Earnings Call Transcript: Q2 2023

Aug 8, 2023, 4:30 PM EDT - 2 years ago

Revolution Medicines Earnings Call Transcript: Q2 2023


Revolution Medicines Transcript: M&A Announcement

Aug 1, 2023, 8:30 AM EDT - 2 years ago

Revolution Medicines Transcript: M&A Announcement


Revolution Medicines Earnings Call Transcript: Q1 2023

May 8, 2023, 4:30 PM EDT - 3 years ago

Revolution Medicines Earnings Call Transcript: Q1 2023


Revolution Medicines Earnings Call Transcript: Q4 2022

Feb 27, 2023, 4:30 PM EST - 3 years ago

Revolution Medicines Earnings Call Transcript: Q4 2022


Revolution Medicines Transcript: JPMorgan Healthcare Conference

Jan 10, 2023, 2:15 PM EST - 3 years ago

Revolution Medicines Transcript: JPMorgan Healthcare Conference


Revolution Medicines Earnings Call Transcript: Q3 2022

Nov 7, 2022, 8:30 AM EST - 3 years ago

Revolution Medicines Earnings Call Transcript: Q3 2022


Revolution Medicines Earnings Call Transcript: Q2 2022

Aug 9, 2022, 4:30 PM EDT - 4 years ago

Revolution Medicines Earnings Call Transcript: Q2 2022


Revolution Medicines Earnings Call Transcript: Q1 2022

May 9, 2022, 10:05 AM EDT - 4 years ago

Revolution Medicines Earnings Call Transcript: Q1 2022


raticals
raticals Apr. 27 at 1:30 PM
$CMPX genuinely asking why is this stock worth a supposed bag of crap but extends life from liver death by 8 months but $RVMD extendes life for pancreatic death by eight month but the stock is worth a mountain of gold?
0 · Reply
Florestan
Florestan Apr. 27 at 6:31 AM
$RVMD $263 for starter. RVMD will go on to become another Merck.
1 · Reply
Skoufc1
Skoufc1 Apr. 27 at 1:08 AM
$RVMD Mentioned on 60 minutes tonight.
0 · Reply
jdlman
jdlman Apr. 26 at 11:43 PM
$RVMD not to late to enter ?
2 · Reply
Skoufc1
Skoufc1 Apr. 26 at 8:36 PM
$RVMD Life Sciences Capital raises price target to.$263 for RVMD.
0 · Reply
Skoufc1
Skoufc1 Apr. 26 at 5:07 PM
$RVMD Life Science has RVMD as a buy and raises PT to $263. I think think this is the highest PT after Stifel bumped it up $215.
0 · Reply
PhantomZ
PhantomZ Apr. 26 at 2:05 AM
$RVMD nice data! Another highly promising Paradigm Shift will be X-ray activation of Rutherin in the destruction of Tumors. 100% CR and survival in animal models. Can’t wait till they release Pancreatic cancer data….https://stockhouse.com/news/press-releases/2026/04/13/theralase-r-reports-complete-response-with-x-ray-activated-rutherrin-r-in-musclec.
1 · Reply
LiveCommander
LiveCommander Apr. 25 at 9:56 PM
People who comment on $RVMD RM-055 preclinical data as predicting replacement to Pan RAS molecule glues should try to understand how the drug works from detailed slides at RVMD website. Daraxonrasib causes some level of GTP hydrolysis and contributes to enhancing RAS off$ERAS and $ANL ) also kill cell lines with RAS amplification. Phase 1 to start in q 4. And people need to stop being ahead of themselves. Although Cool discovery but no details on how it enhances hydrolysis.
0 · Reply
AppleStar
AppleStar Apr. 25 at 8:52 PM
$RVMD It got to $150. I was just two weeks early in this prediction. Looking forward to ASCO in a couple of weeks. Or will they get bought out before?
2 · Reply
BixbyKnolls
BixbyKnolls Apr. 25 at 6:48 PM
$IBRX He thinks $RVMD complimentary to IBRX.
0 · Reply
alexcampbello
alexcampbello Apr. 25 at 2:37 AM
$RVMD Revolution, based near San Francisco, said it was planning to seek regulatory approval soon for the treatment, which the Food and Drug Administration has already designated for a fast-track review. Shared via <a href=http://www.pressreader.com>PressReader.com</a> – Connecting People Through News <p><strong>PressReader – Connecting People Through News</strong>.</p><p>NewspaperDirect Inc. dba PressReader, 200-13111 Vanier Place, Richmond BC V6V 2J1, Canada<br /></p><p>©2003-2026 PressReader, All rights reserved. <a href=http://www.pressreader.com/help/TermsOfUse>Terms of Use</a>  |  <a href=http://www.pressreader.com/help/PrivacyPolicy>Privacy Policy</a>
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 24 at 8:28 PM
$SLS $RVMD $ABVX the DumbasF short idiots Have Been SELLING TO BLACK ROCK... HAHAHA now they are SO FFFF"D...
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 24 at 6:37 PM
$SLS $ABBV $RVMD a Basic Fact Everyone should understand: Harvard Prof., Dr. Amrein enhanced dosing, increasing Potency, above and beyond the Phase 2B Results Published at ASH - Virtually Guarantees SLS009 FDA APPROVAL for a BUYER - Results in the Ongoing RANDOMIZED Pivotal P2B Expansion into Front Line AML-MR - will be better than the Previous Results - in end stage.
0 · Reply
1986iamwallstreet
1986iamwallstreet Apr. 24 at 5:32 PM
$RVMD another one that’s going to get taken over soon
3 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 24 at 4:24 PM
$SLS $RVMD added $15B in Market Value the day it released its Positive P3 Results. $ABVX was a $5 Stock, and doubled to $10 in the days before its P3 was released - SLS will be doing this - there was a T1 Trading Halt at $10. and Gap Up 600% Opening at $60 Per Share - and it KEPT CLIMBING to a High of $148, as the market Digested the Real Value / and Revenue Potential. From $5 to $148 on P3 DATA .... SOMETHING SIMILAR WILL BE HAPPENING HERE > IT is Inevitable.
0 · Reply
Dritacca
Dritacca Apr. 24 at 11:34 AM
0 · Reply
Dritacca
Dritacca Apr. 24 at 11:34 AM
$RVMD KRAS-mutant tumors are often “cold” or immunosuppressive. KRAS inhibition can make them more visible to the immune system (e.g., via immunogenic cell death or neoantigen release), while Anktiva supercharges the effector cells (NK + CD8 T cells) needed to attack them. This is similar to how KRAS inhibitors are already being paired with checkpoint inhibitors (PD-1/PD-L1) in trials, with encouraging early signal
1 · Reply
Skoufc1
Skoufc1 Apr. 24 at 11:24 AM
$RVMD LONGS ride the wave and get the reward. PATIENCE
0 · Reply
Alt_Fuel
Alt_Fuel Apr. 24 at 8:29 AM
$VSTM Verastem partner in KRAS ON / OFF " GenFleet Therapeutics " - New 52 Week High on April 24, 2026 $ANL $ELTX $ERAS $RVMD Apr. 23, 2026-- Verastem Oncology $VSTM will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-report-first-quarter-2026-financial-results
1 · Reply
Alt_Fuel
Alt_Fuel Apr. 24 at 7:33 AM
$VSTM annual meeting led by Verastem Oncology GenFleet’s partner. Hong Kong - Jinfang / GenFleet Medicine-B (02595) rose over 3% as two preclinical studies of GFH375 / VS-7375 were selected for breakthrough research abstracts. Zhitong Finance - Apr 23, 2026 GENFLEET-B +11.14% $ERAS $RVMD https://www.moomoo.com/news/post/68806318/hong-kong-stock-movement-jinfang-medicine-b-02595-rose-over?chain_id=bJoStPvEgQD6bO.1kum6kn&futusource=news_web_stockpagenews&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A57%2C%22f%22%3A%22mm%2Fstock%2F02595-HK%2Fnews%22%7D&lang=en-us&ns_stock_id=87363929770531&report_id=62142513&report_type=stock&src=43&stock_news_tab=news&level=1&data_ticket=1761581596149365
0 · Reply
Mattyk7
Mattyk7 Apr. 24 at 4:10 AM
$RVMD Stock price is so overbought, compared to others in same sector. $VSTM is on track to have larger studies with better outcomes, and has a drug already approved.
0 · Reply
shopno
shopno Apr. 24 at 12:22 AM
$SLS At the end the management is doing no charity here, so they must pay themselves handsomely. It’s not a big matter if$SLS gets sold for / hits the market cap $20B or 10% diluted $18B. Take a look at $RVMD — maybe they will get acquired for 2x of $SLS valution. The CEO owns ~$150M worth stocks, he just sold $18M past week. Compare that to Stergiou’s peanuts holding atm.
1 · Reply